Intratumoral injection—the boosting of the immune response against metastatic melanoma by the direct injection of immunotherapy into tumor masses—is a promising treatment method because it’s effective ...
Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...
Ad.IL-12 was administered in doses ranging from 2.5 × 10 10 to 3 × 10 12 viral particles, to seven cohorts of patients with advanced pancreatic, colorectal, or primary liver malignancies. Patients ...
Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an investigational immunotherapeutic for solid tumors and subsidiary of Beyond Air ...
AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R2) versus placebo ...
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in ...
LOS ANGELES – Researchers at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute are working to develop a non-surgical approach to brain cancer that uses radiation and the injection of specially ...
Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies ...
Today, the U.S. Food and Drug Administration approved Stelfonta (tigilanol tiglate injection) to treat dogs with non-metastatic, skin-based (cutaneous) mast cell tumors (MCTs). The FDA is also ...
SILVER SPRING, Md., Nov. 16, 2020 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Stelfonta (tigilanol tiglate injection) to treat dogs with non-metastatic, skin-based (cutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results